EQ•benzinga•
Equillium Announced Topline Data From The Phase 3 EQUATOR Study Evaluating Itolizumab In First-line Treatment Of Patients With Acute Graft-versus-host Disease. The Study Results Did Not Demonstrate A Meaningful Difference In Complete Response Or Overall R
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 27, 2025 by benzinga